UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 


FORM 8-K
 


  CURRENT REPORT
  Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
December 12, 2012
 

Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
 

 
Delaware  0-16005 22-2328609
(State or other jurisdiction of
(Commission File Number)  (I.R.S. Employer
incorporation or organization)   Identification No.)
 
81 Fulton Street, Boonton, New Jersey 07005
(Address of principal executive offices) (Zip Code)
 
(973) 265-1100
(Registrant’s telephone number, including area code)

Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 
 
 
 
 
Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 12, 2012, Gregory T. Mayes, President and General Counsel, and member of the Board of Directors of Unigene Laboratories, Inc., gave notice of his resignation of employment and as a member of the Board of Directors to pursue new opportunities.  The resignation will be effective as of December 31, 2012.


 
Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
UNIGENE LABORATORIES, INC.
 
       
 
By:
/s/ Ashleigh Palmer  
   
Chief Executive Officer
 
 
Date: December 14, 2012